Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into the clinic Cambridge, UK, 18 February 2025 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that […]